# Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

> **NCT02756897** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 234 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT02756897
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-07
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02756897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02756897, "Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02756897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*